Patient Characteristics
| Characteristic | n |
|---|---|
| No. of patients included | 10 |
| No. of evaluable patients* | 8 |
| No. of lesions on PET | 47 |
| No. of evaluable lesions† | 42 |
| No. of lesions ≥ 10 mm at baseline (CT or MRI) | 32 |
| Median patient age at baseline (y) | 62 |
| No. of females (n) | 3 (38) |
| No. of PET scans per patient (n) | |
| 1 | 4 (50) |
| 2 | 4 (50) |
| Immunotherapy regimen (n) | |
| Anti-CTLA4 + Anti-PD-1 | 5 (62) |
| Anti-PD1 | 3 (38) |
| No. of patients by treatment response (RECIST, version 1.1) (n) | |
| Complete response | 0 (0) |
| Partial response | 2 (25) |
| Stable disease | 2 (25) |
| Progressive disease | 4 (50) |
* Including 6 patients with brain metastases.
↵†Lesions that were detected at baseline and follow-up by MR or CT imaging.
Data in parentheses are percentages.